Regulatory & Submissions · NDA Support
NDA Submission Support — Manufacturing and Controls
The short answer
By NDA, the manufacturing story has to be complete: a justified control strategy, validated process, qualified methods and a site that can demonstrate all of it during a pre-approval inspection. We build and review that content, and we assess the site against what the application claims.
Why this matters
- Module 3 commitments are inspected. A control strategy described in the application but not implemented at the site is a serious finding.
- Process validation at NDA stage is expected to be lifecycle-based, with Stage 3 planned rather than deferred.
- Post-approval change burden is set by how the application is written. Over-specification creates years of supplements.
Applicable regulations and standards
- 21 CFR Part 314
- NDA content and format, supplements and annual reports.
- 21 CFR Part 211
- cGMP for finished pharmaceuticals evaluated at the site.
- ICH Q8 / Q11 / Q12
- Development, drug substance manufacture and lifecycle change management.
- FDA Process Validation Guidance (2011)
- The three-stage lifecycle expectation behind the validation package.
What our consultants actually do
- Author and review Module 3 CMC content for drug substance and drug product
- Build the control strategy narrative linking CQAs, CPPs and in-process controls
- Assess the process validation package for defensibility before it is filed
- Structure specifications and post-approval change strategy to limit unnecessary supplements
- Run pre-approval inspection readiness assessments with former FDA investigators
- Prepare site subject matter experts to explain validation and control rationale
Across the product lifecycle
01 / DEVELOP
Characterization data organized to justify ranges in the filing.
02 / SCALE
Commercial equipment differences resolved before PPQ.
03 / TRANSFER
Process and method transfer documented for the commercial site.
04 / VALIDATE
PPQ executed against justified criteria; report defensible.
05 / MANUFACTURE
Routine production consistent with the filed control strategy.
06 / MAINTAIN
CPV, annual reports and change-driven supplements.
Problems we are usually called about
- Filed parameter ranges narrower than the process can reliably hold
- PPQ deviations closed without technical assessment of impact on the validation conclusion
- Methods transferred to the QC site but never formally validated there
- Control strategy described in Module 3 with no equivalent in site procedures
- No continued process verification plan at time of filing
Typical deliverables
- Module 3 CMC authoring and technical review
- Control strategy summary and specification justification
- Validation package assessment and remediation plan
- Pre-approval inspection readiness report
- Post-approval change management strategy
Frequently asked
- Can you review a CMC section another firm wrote?
- Yes, and this is a common engagement. We read it the way an investigator would: does the site do what this says, and can it prove it?
- How do you reduce post-approval supplement burden?
- By filing ranges and descriptions that reflect real process capability, using established conditions thinking, and building a change classification step into change control so decisions are consistent.
References
More for regulatory & submissions
Technical, manufacturing and quality support for US FDA submissions — written by people who have reviewed and inspected against them.
- 510(k) SupportA 510(k) is an argument for substantial equivalence, supported by evidence your quality system has to be able to produce on demand.
- PMA SupportA PMA is reviewed alongside a pre-approval inspection of the manufacturing site, which means the manufacturing section is not paperwork — it is a description of a facility that will be examined.
- De Novo SupportA De Novo asks FDA to create a classification, which means the submission has to propose the controls that will make the device type safe and effective.
- IND SupportFor an IND, the section that most often holds up a program is CMC.
- ANDA SupportGeneric applications are decided as much on manufacturing quality and data credibility as on bioequivalence.
- BLA SupportFor a biologic, the process is a substantial part of the product.
- IDE SupportAn IDE requires a description of how the investigational device is made and controlled, and design controls apply even though the device is not yet cleared.
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.